|Bid||54.50 x 100|
|Ask||69.85 x 100|
|Day's Range||58.00 - 60.20|
|52 Week Range||17.10 - 70.75|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 20, 2018 - Feb 26, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||45.67|
Foundation Medicine, Inc. today announced that new data generated with FoundationOne®Heme, its comprehensive genomic profiling assay for hematologic malignancies and sarcomas, will be presented at the American Society of Hematology Annual Meeting.
Michael Pellini, chairman of genomic diagnostics company Foundation Medicine Inc., has joined Section 32 as a managing partner.
Determining which cancer drugs will work best in each individual patient could become easier following this important FDA approval.
The government approved the company's new test that finds flaws in 324 genes that can drive cancer growth. Foundation Medicine shares (FMI) rose 18% today, on 14-times recent average volumes, to close at $62.60. Medicare and Medicaid administrators also indicated their willingness to cover the test, which Foundation calls FoundationOne CDx. Foundation says it will help identify patients who might benefit from any of 17 targeted therapies, as well as newer immunotherapies.
Foundation Medicine hit a high after U.S. regulators approved its test to match cancer patients to FDA-approved therapies.
Foundation Medicine, Inc. today announced that the U.S. Food and Drug Administration approved FoundationOne CDx™, the company’s comprehensive companion diagnostic test for solid tumors.
Investors in Foundation Medicine (FMI) need to pay close attention to the stock based on moves in the options market lately.
Cancer treatment is moving rapidly toward personalized medicine and precision medicine thanks to genetic insight.
Foundation Medicine, Inc. today reported financial and operating results for its third quarter ended September 30, 2017. Results and business highlights for the quart
Foundation Medicine, Inc. today announced that the company will present validation data for FoundationOne CDx, its comprehensive genomic profiling assay, at the International Association for the Study of Lung Cancer 18th World Conference on Lung Cancer .
Foundation Medicine, Inc. today announced that financial results for the company's third quarter ended September 30, 2017 will be released on Wednesday, November 1, 2017.
Foundation Medicine, Inc. today announced the appointment of Tom Civik to the role of chief commercial officer. Mr. Civik brings to Foundation Medicine more than two decades of commercial and operational experience with global biopharmaceutical organizations, most recently having served as a vice president and officer for Genentech, as well as previously serving in increasingly complex commercial positions ...
NEW YORK , Oct. 3, 2017 /PRNewswire/ -- Foundation Medicine, Inc. (FMI) Lifshitz & Miller announces an investigation on behalf of FMI investors concerning whether FMI issued false and misleading statements ...
Foundation Medicine, Inc. today announced that it received approval from the New York State Clinical Laboratory Evaluation Program for its FoundationACT® blood-based circulating tumor DNA assay.